GBCA-enhanced MRI does not influence MS progression
Researchers found evidence of gadolinium accumulation in the brains of multiple...Read more on AuntMinnie.comRelated Reading: Study shines more light on GBCA-related adverse reactions Contrast not needed for follow-up MRI on MS patients MRI shows drug slows brain atrophy in MS patients MRI links iron in the brain to multiple sclerosis MRI shows potentially better indicator for MS progression
Authors: Zanghì A, D'Amico E, Patti F Abstract IntroductionTherapeutic armamentarium in Multiple Sclerosis (MS) has radically changed in the last few decades due to the development of disease modifying treatments (DMTs) with highly selective mechanisms of action.Areas coveredIn this review, the authors will focus on the current role of immunosuppressive DMTs in the management of the relapsing remitting form of MS (RRMS), moving from the rationale of its use and looking at the possibility to design an idealistic scenario of a personalized approach for each single patient.Expert opinionQuestions remain open about...
This study was conducted between January 1, 2019, and July 25, 2019, at the neurology and biochemistry clinics of two different tertiary hospitals simultaneously. Overall, 50 RRMS patients with migraine, 50 RRMS patients without migraine, and 50 healthy volunteers were included in the study. The participants’ vitamin D, VITDBP, VITDR, hs-CRP, SOD, CAT, GSH-Px, TAS, TOS, and OSI values were measured.ResultsThe vitamin D and VITDR values of the RRMS patients with migraine were lower than those of the RRMS patients without migraine (respectively, p = 0.014, p
Publication date: Available online 23 January 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): Arturo de Falco, Marta De Simone, Florindo d'Onofrio, Daniele Spitaleri, Fabrizio Antonio de FalcoAbstractMultiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination and neurodegeneration in the central nervous system. Recent studies suggested that patients with MS might have a greater risk of ischaemic stroke (IS). IS treatment with intravenous alteplase (IVA) in MS has rarely been reported. This could be due to the challenging diagnosis between acute IS and MS relapse, considering tha...
Persons with multiple sclerosis (MS) are sometimes treated with high-dose immune suppressive or cytotoxic drugs and an autotransplant. Therapy-related mortality (TRM) has decreased to
G-CSF mobilization of hematopoietic stem cells (HSCs) requires 4-7 days of injections that provide unreliable collections. G-CSF is associated with significant side effects and potential for fatal complications in some patient populations (e.g. sickle cell disease, multiple sclerosis). MGTA-145 is an analog of the chemokine GRO β that activates CXCR2 and with plerixafor rapidly mobilizes HSCs in mice and non-human primates. The combination promises to be a same-day mobilization regimen that does not require G-CSF.
Multiple sclerosis (MS) is an inflammatory, demyelinating and neurodegenerative disease of the central nervous system (CNS) that causes a whole spectrum of neurological disorders associated with a profound decrease in the quality of life of affected patients. Currently, autologous hematopoietic cell transplantation (ASCT) is a validated therapeutic approach and has been shown to be superior to new immunomodulatory agents. However, the impact of these therapies on the quality of life of patients with MS is unknown.
Myeloablative and immunoablative therapy followed by autologous hematopoietic stem cell transplantation (AHSCT) has been shown to be effective in patients with highly active relapsing multiple sclerosis (RMS) with continued activity despite treatment with approved disease-modifying therapies (DMTs). However, AHSCT has not been formally compared to the contemporary high efficacy biologic DMTs in a clinical trial.
Resetting the immune system through autologous hematopoietic stem cell transplant (autoHSCT) is a highly effective treatment in patients with autoimmune diseases (AID). AutoHSCT achieved long-term remission in patients with relapsed refractory and secondary progressive multiple sclerosis (Muraro 2017), superior to their previous standard of care (Burt 2019). AutoHSCT in scleroderma patients achieved superior outcomes in two randomized studies (Tyndall 2014, Sullivan 2018). These impressive results are achieved by both eradication of autoreactive immune effector cells and re-establishment of a self-tolerant immune system, i...
(Netherlands Institute for Neuroscience - KNAW) Researcher of the Netherlands Institute for neuroscience found that myelin, the sheath around neurons, creates a coaxial cable producing multiple waves of electrical potentials traveling in a more complicated manner than was envisioned earlier. These findings allow us to create better theories and tools to understand demyelinating diseases, including the most common neurological disorder, multiple sclerosis. The paper has been published in the prestigious scientific journal Cell.